Aug 2026
MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.
It is demonstrated that activation of β-catenin is associated with a poor prognosis in melanoma and inhibiting the enzymatic activity of MICAL2 offers a promising and innovative strategy to improve outcomes in β-catenin-driven melanoma.
P. Sohier, J. Raymond, Zackie Aktary et al.
· Cell Death and Differentiati... · 0 citations